Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 15 of 15 publications.
Skip to main content
Chirila C, Gilligan TM, Gilsenan A, Price M, Hollis K, Calingaert B, Zografos L, Andrews E. A comparison of factors influencing patient knowledge: results across selected REMS surveys. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.
Gilsenan A, Hollis K, Zografos L, Calingaert B, Andrews E. Examination of respondent bias and patient characteristics in multiple REMS assessment surveys. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.
Gilsenan A, Harris DH, Midkiff K, Wright J, Andrews E. Linking with multiple state cancer registries for safety surveillance study – Is it feasible? Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.
Midkiff KD, Harris D, Gilsenan AW, Wu Y, Andrews EB. Drug safety studies using cancer registry data: confluence of elements impacting the interview response rate. Poster presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 14, 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug 1; 20(Suppl. 1):S231. doi: 10.1002/pds.2206
Midkiff KD, Gilsenan AW, Wu Y, Harris DH, Masica D, Andrews EB. Using cancer registry data to advance the science of drug safety: results from an ongoing postmarketing drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Conference; June 21, 2011. Lexington, KY.
Mintz ML, Yawn BP, Mannino DM, Donohue JF, Hanania NA, Grellet CA, Gilsenan AW, McLeod LD, Dalal AA, Raphiou IH, Prillaman BA, Crater GD, Cicale MJ, Mapel DW. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May 1;86(5):375-81.
Levitan BS, Andrews EB, Gilsenan A, Ferguson J, Noel RA, Coplan PM, Mussen F. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011 Feb 1;89(2):217-24. doi: 10.1038/clpt.2010.280
Andrews EB, Midkiff KD, Gilsenan AW, Harris DH. Collaboration with multiple state cancer registries for a data linkage drug safety surveillance study – yes you can!. Poster presented at the North American Association of Central Cancer Registries Annual Conference; 2011.
Gilsenan AW, Midkiff KD, Harris DH. Opportunities for improving the use of cancer registry data in drug safety studies: factors influencing interview response rate. Presented at the North American Association of Central Cancer Registries Annual Conference; 2011.
Midkiff KD, Gilsenan AW, Harris DH, Wu Y, Masica D, Andrews EB. Exposure to possible osteosarcoma risk factors in a US postmarketing osteosarcoma surveillance study. Poster presented at the Scandinavian Sarcoma Group Annual Meeting; 2011.
Burdett AN, Gard CC, Longo CJ, Raskin J, Gilsenan A, Hopkins JS, Miller DP. Prevalence and costs of difficult-to-treat depression in a Canadian claims database. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux.
Leone P, Fleming DT, Gilsenan A, Li L, Justus S. Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. Sex Transm Dis. 2004 May 31;31(5):311-6.
Lopez R, Gilsenan AW, Zhou X, Myrie L. Attempt – Assessment methodology and study population description. Poster presented at the Sanofi-Aventis Recherche et Développement's Expert Meeting; May 2004.
West R, Curry SJ, Fiore MC, Sullivan SD, Neighbors D, Gilsenan AW, Smadja E, Lavaud V. Attempt cohort: weight gain concern of smokers intending to quit. Poster presented at the 10th Annual Scientific Sessions of the Society for Research on Nicotine and Tobacco; February 2004. Scottsdale, AZ.
Andrews EB, Gilsenan A, Cook SF. Therapeutic Risk Management Interventions: feasibility and Effectiveness. J Am Pharm Assoc. 2004 Jan 1;44(4):491-500.